

New/Changed Dose

Prescriber Information								
Prescriber Name:				MD	DO	NP	PA	NPI:
Office Contact:				Practice Name / Collaborating MD:				
Address:			City:		State:		Zip:	
Phone:		Fax:						

Patient Information • PLEASE SEND COPY OF INSURANCE CARD								
Patients Name:		Last 4 Digits of SS#:		DOB: / /	Sex: M F	Weight:	Height:	Diabetic? Y N
Address:			City:		State:		Zip:	
Home Phone:		Work/Cell:		HIPAA Contact:		Emergency #:		
Interpreter Needed? Y N	Allergies: Y N If Yes, list allergies:							

Insurance Information					
Primary Insurance:		Policy ID:	Group #:	BIN:	PCN:
Policyholder Name:			Policyholder DOB: / /		

Dermatology • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES							
ICD-10/Diagnosis Code:	Psoriasis Vulgaris (L40.0)	Other Psoriasis (L40.8)	Psoriasis unspecified (L40.9)	Psoriatic Arthritis (L40.5)	Hidradenitis Suppurativa (L73.2)	Chronic Urticaria (L50.8)	
Atopic Dermatitis (L20.9)		TB/PDD Test Given: Y N	Date of Neg. Test: / /	HBV Positive? Y N If Yes, is patent currently treated? Y N			
Prior Treatment? Y N	BSA Affected (%):		Affected Areas: Palms Soles Head Neck Genitalia Other:				

Gastroenterology • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES				
ICD-10/Diagnosis Code:	K50.__(Crohn's Disease)	K51.__(Ulcerative Colitis)	Other:	
Date of Diagnosis: / /		Date of Negative TB Test: / /		Prior Treatment? Y N

Rheumatology • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES					
ICD-10/Diagnosis Code:	M32.9 Active Systemic Lupus Erythematosus	M45.9 Ankylosing Spondylitis	M08.0 Juvenile Idiopathic Arthritis	L40.59 Psoriatic Arthritis	L40.54 Psoriatic Juvenile Arthritis
M06.9 Rheumatoid Arthritis M45.A ____ Non-Radiographic Axial Spondyloarthritis Other:					
Date of Diagnosis: / /		Date of Neg. TB Test: / /	Any prior treatment? Y N		

Notes to Pharmacy

Prescription Information			
	Quantity/Dose	Sig	Refills
ACTEMRA® (tocilizumab)	Number of 80mg/4ml vials: _____ Number of 200mg/10ml vials: _____ Number of 400mg/20ml vials: _____	Infuse _____ mg IV over 60 minutes every 4 weeks Infuse _____ mg IV over 60 minutes every 2 weeks	
BENLYSTA® (belimumab)	Number of 120mg/5ml vials: _____ Number of 400mg/20ml vials: _____	Starter Dose: Infuse _____ mg IV over 1 hour at weeks 0, 2, and 4	No Refills
		Maintenance Dose: Infuse _____ mg IV over 1 hour once every 4 weeks	
COSENTYX® (secukinumab)	Number of 125mg/5ml vials: _____	Starter Dose: Infuse _____ mg at week 0 No starter dose	No Refills
		Maintenance Dose: Infuse _____ mg every 4 weeks	
ENTYVIO® (vedolizumab)	2 vials (300mg each)	Starter Dose: Infuse 300mg IV over 30 minutes at weeks 0 and 2	No Refills
	1 vial (300mg)	Maintenance Dose: Infuse 300mg IV over 30 minutes once every 8 weeks beginning at week 6	
OMVOH™ (mirikizumab-mrkz)	1 vial (300mg/15ml) 3 vials (300mg/15ml)	UC Starter Dose: Infuse 300mg IV at weeks 0, 4 and 8. Begin SQ maintenance dosing at week 12. CD Starter Dose: Infuse 900mg IV at weeks 0, 4 and 8. Begin SQ maintenance dosing at week 12.	2 Refills
ORENCIA® (abatacept)	Number of 250mg vials: _____	Starter Dose: Infuse _____ mg IV at weeks 0 and 2	No Refills
		Maintenance Dose: Infuse _____ mg IV at week 4 and every 4 weeks thereafter	

By signing this form and utilizing our services, you are authorizing Meijer and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

Prescriber Signature	Date	Prescriber Signature	Date
----------------------	------	----------------------	------

Substitution Permitted

Dispense as Written

If brand is required, please write "DAW" in the box to the right.